Fludarabine

Active ingredient: Fludarabine Phosphate

In short: Fludarabine Phosphate Injection is indicated: as a component of a combination regimen for the treatment of adults with B-cell chronic lymphocytic leukemia (CLL); for the treatment of adults with B-cell CLL who have not responded to or whose disease has progressed during treatment with at least one a

Forms & strengthsInjection: 50 mg/2 mL (25 mg/mL). Fludarabine Phosphate Injection, USP is supplied as a clear, colorless to almost colorless sterile solution in single-dose vials.
LabelHisun Pharmaceuticals USA, Inc.
Label updatedSep 21, 2026

What is Fludarabine used for?

Fludarabine Phosphate Injection is indicated:

as a component of a combination regimen for the treatment of adults with B-cell chronic lymphocytic leukemia (CLL);

for the treatment of adults with B-cell CLL who have not responded to or whose disease has progressed during treatment with at least one alkylating-agent containing regimen.

Fludarabine dosage

In Combination with Cyclophosphamide and Rituximab

The recommended dosage of Fludarabine Phosphate Injection is 25 mg/m

2administered intravenously over 30 minutes daily for the first three days (Days 1 to 3) of each 28-day cycle for 6 cycles or until unacceptable toxicity or disease progression, in combination with cyclophosphamide 250 mg/m

2administered intravenously daily for three days (Days 1 to 3), and rituximab 375 mg/m

2administered intravenously on Day 1 of the first cycle, followed by rituximab 500 mg/m

2on Day 1 of subsequent cycles.

Refer to the cyclophosphamide and rituximab prescribing information for additional dosing information as appropriate.

Single Agent

The recommended dosage of Fludarabine Phosphate Injection is 25 mg/m

2administered intravenously over 30 minutes daily for five consecutive days (Days 1 to 5) of each 28-day cycle.

Reduce the Fludarabine Phosphate Injection dosage for patients with renal impairment as shown in Table 1. Closely monitor patients with renal impairment for adverse reactions.

Table 1: Dosage Modifications for Renal Impairment

Cre

atinine Clearance

(Estimated by Cockcroft-Gault equation) | Recommended Dosage

​50 – 79 mL/min | ​20 mg/m

2

30 – 49 mL/min | 15 mg/m

2

< 30 mL/min | A dosage has not been established.

Fludarabine Phosphate Injection is a hazardous drug. Follow applicable special handling and disposal procedures.

1

Dilute Fludarabine Phosphate Injection in 100 mL to 125 mL of 5% Dextrose Injection or 0.9% Sodium Chloride Injection.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Infuse diluted Fludarabine Phosphate Injection intravenously over 30 minutes.

Fludarabine Phosphate Injection contains no antimicrobial preservative. If not used immediately, discard the unused portion within 8 hours after opening the single-dose vial.

Do not mix Fludarabine Phosphate Injection with other drugs.

Warnings & precautions

Do not take this medicine if: None.

Severe central nervous system (CNS) adverse reactions, including coma, seizures, agitation and confusion, can occur in patients treated with Fludarabine Phosphate Injection. CNS adverse reactions may occur either early or late after the initiation of Fludarabine Phosphate Injection (range 7 to 225 days).

CNS adverse reactions are dose dependent and occur at greater incidence and severity in patients treated at doses higher than the recommended dose of Fludarabine Phosphate Injection

.

Monitor patients for signs and symptoms of neurologic toxicity during and after treatment with Fludarabine Phosphate Injection. Consider delaying or discontinuing Fludarabine Phosphate Injection if neurotoxicity occurs. Do not administer Fludarabine Phosphate Injection at doses higher than the recommended dose.

Advise patients that Fludarabine Phosphate Injection may reduce the ability to drive or use mechanical equipment, since fatigue, weakness, visual disturbances, confusion, agitation, or seizures may occur.

Fludarabine phosphate can cause severe and fatal myelosuppression, which may include neutropenia, thrombocytopenia, or anemia. Cases of trilineage bone marrow hypoplasia or aplasia resulting in pancytopenia, sometimes resulting in death, have been reported.

The median time to nadir of counts was approximately 13 days (range, 3 to 25 days) for granulocytes and 16 days (range, 2 to 32 days) for platelets. The duration of the cytopenia in reported cases has ranged from approximately 2 months to approximately 1 year.

Monitor complete blood counts at baseline, prior to and during each treatment cycle, and as clinically needed. Consider dosage delays, dose reductions, or permanent discontinuation if recovery has not occurred by the first day of the next scheduled cycle. …

Fludarabine side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Neurologic Toxicities

Myelosuppression

Autoimmune Cytopenias

Transfusion Associated Graft-Versus-Host Disease

Tumor Lysis Syndrome

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

B-cell Chronic Lymphocytic Leukemia

Combination with Cyclophosphamide and Rituximab

The safety of Fludarabine Phosphate Injection for the treatment of adults with B-cell CLL as a component of a combination regimen was derived from the published literature

. The safety of Fludarabine Phosphate Injection for the treatment of adults with B-cell CLL as a component of a combination regimen was consistent with the known safety profile of fludarabine phosphate.

Single Agent

The safety of fludarabine phosphate was evaluated in two single-arm open-label studies (MDAH and SWOG) in adult patients (n=133) with CLL refractory to at least one prior alkylating-agent containing regimen

.

In these two clinical trials, 22% of the patients treated with fludarabine phosphate had fatal adverse reactions, with approximately 50% of these due to infection. …

Drug interactions

Avoid use of Fludarabine Phosphate Injection in combination with pentostatin due to the risk of severe and fatal pulmonary toxicity

About this medicine

Fludarabine Phosphate Injection, USP contains fludarabine phosphate, a nucleoside metabolic inhibitor.

The chemical name for fludarabine phosphate is 9H-Purin-6-amine, 2-fluoro-9-(5-0-phosphono-β-D-arabinofuranosyl) (2-fluoro-ara-AMP). The molecular formula of fludarabine phosphate is C

10H

13FN

5O

7P (MW 365.2) and has the following chemical structure:

Each mL contains 25 mg of the active ingredient fludarabine phosphate (equivalent to 19.5 mg Fludarabine), 1.78 mg disodium phosphate dihydrate, water for injection and sodium hydroxide to adjust pH to 7.5. The pH range for the final product is 7.3 to 7.7. Fludarabine Phosphate Injection, USP is a sterile solution intended for intravenous administration.

How it works: Fludarabine phosphate is rapidly converted to active 2-fluoro-ara-ATP , which appears to inhibit DNA synthesis through inhibition of DNA polymerase alpha, ribonucleotide reductase and DNA primase. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 291f6ee2-f5d2-ae6c-e063-6294a90a5951. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate